3TR Project: Crossing Disease Borders to Reshape European Research
The 3TR project aims to transform the understanding and treatment of immune-mediated diseases, with its core principles in precision medicine.
At a time when chronic diseases place growing pressure on patients and health systems alike, the 3TR project is rewriting how science is done.
The project is a groundbreaking effort to understand the shared mechanisms driving immune-mediated diseases and to pave the way for truly personalised medicine across Europe.
Backed by €80 million in funding through the Innovative Medicines Initiative (IMI2), 3TR unites 69 organisations across 15 countries, including eight major pharmaceutical companies and leading academic institutions.
This collaborative effort is one of the largest ever launched in the field of immunology, following Europe’s vision of breaking down scientific silos and advancing research that serves the public good.
3TR – short for Taxonomy, Treatment, Targets, and Remission
Author's summary: 3TR project transforms immune-mediated diseases research.
- 69 organisations across 15 countries
- €80 million in funding through IMI2
- 8 major pharmaceutical companies and leading academic institutions
More News
- The children are starving; God is screaming – Baptist News Global
- Best Dog-Friendly Hotel Chains for Road Trips: Complete Guide - Amazingworld
- Chase on the Case: Government shutdowns hit home
- Heckler launches in Shanghai: The band is back together to redefine creative production in Asia
- “Frankenstein” strays from source material